Why the study?
The proportion of patients eligible for the ISCHEMIA trial and how their characteristics and outcomes compare with ineligible patients in contemporary clinical practice remained unassessed.
What proportion of real-world stable CAD patients are eligible for the ISCHEMIA trial, and how do their outcomes compare to ineligible patients?
What proportion of real-world stable CAD patients are eligible for the ISCHEMIA trial, and how do their outcomes compare to ineligible patients?
Only a small fraction (4%) of real-world stable CAD patients meet ISCHEMIA trial eligibility, and these patients have an extremely low annual risk of adverse events compared to ineligible patients.
No takes yet. Share an insight, caveat, or question.
Most real-world stable CAD patients fall outside ISCHEMIA criteria; leaves open optimal management strategies for this majority population.
Luca et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: